Simcere Zaiming Overview
- Year Founded
-
2020
- Status
-
IPO Registration
- Employees
-
2,161
- Latest Deal Type
-
IPO
- (Announced)
- Investors
-
5
Simcere Zaiming General Information
Description
Developer and manufacturer of innovative oncology drugs designed for treating cancer patients with unmet clinical needs. The company provides drug development services and commercialization capabilities, enabling healthcare providers and patients with access to first-in-class and best-in-class therapeutic solutions.
Contact Information
Website
www.sparkletx.comCorporate Office
- No. 20, Yiheng Road, Yaogu
- Xiuying District
- Haikou, Hainan 570311
- China
Corporate Office
- No. 20, Yiheng Road, Yaogu
- Xiuying District
- Haikou, Hainan 570311
- China
Simcere Zaiming Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. IPO | 09-Jan-2026 | Announced | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 06-Jun-2025 | Completed | Generating Revenue |
Simcere Zaiming Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Simcere Zaiming Patents
Simcere Zaiming Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026233359-A1 | Macrocyclic compound | Pending | 08-May-2025 | ||
| WO-2026228729-A1 | Benzoheterocyclic compound | Pending | 30-Apr-2025 | ||
| WO-2026200725-A1 | Polypeptide conjugate for detecting internalization efficiency of antibody and antibody-derived molecule, and use thereof | Pending | 24-Mar-2025 | ||
| WO-2026098657-A1 | Heterocyclic compound as mek inhibitor | Pending | 08-Nov-2024 | ||
| WO-2026082031-A1 | Pharmaceutical composition comprising anti-cdh6 antibody or adc thereof | Pending | 14-Oct-2024 |
Simcere Zaiming Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Simcere Zaiming Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Apricot Capital (Shanghai) | Venture Capital | Minority | ||
| China Taiping Investment | Venture Capital | Minority | ||
| SDIC Capital Management | Growth/Expansion | Minority | ||
| Youshan Capital | Venture Capital | Minority | ||
| Zhonghe Capital | Growth/Expansion | Minority |
Simcere Zaiming FAQs
-
When was Simcere Zaiming founded?
Simcere Zaiming was founded in 2020.
-
Where is Simcere Zaiming headquartered?
Simcere Zaiming is headquartered in Haikou, China.
-
What is the size of Simcere Zaiming?
Simcere Zaiming has 2,161 total employees.
-
What industry is Simcere Zaiming in?
Simcere Zaiming’s primary industry is Pharmaceuticals.
-
Is Simcere Zaiming a private or public company?
Simcere Zaiming is a Private company.
-
What is Simcere Zaiming’s current revenue?
The current revenue for Simcere Zaiming is .
-
How much funding has Simcere Zaiming raised over time?
Simcere Zaiming has raised $148M.
-
Who are Simcere Zaiming’s investors?
Apricot Capital (Shanghai), China Taiping Investment, SDIC Capital Management, Youshan Capital, and Zhonghe Capital have invested in Simcere Zaiming.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
